Dr. Khoo Ui Soon - Pathology
Specialist in Pathology
Highlights
- MCHK RegisteredVerified
- Specialist in PathologyBachelor of Medicine, Bachelor of Surgery and Bachelor of Obstetrics, National University of Ireland · MB BCh Irel · Member of the Royal College of Pathologists · Medical degree 1984
- InsuranceBeing compiled｜See details
About
Dr. Khoo Ui Soon is a registered Pathology specialist in Hong Kong.
Education
Specialist in Pathology
- Bachelor of Medicine, Bachelor of Surgery and Bachelor of Obstetrics, National University of IrelandBachelor of Medicine, Bachelor of Surgery and Bachelor of Obstetrics, National University of Ireland1984
- MB BCh Irel1984
- Member of the Royal College of PathologistsMember of the Royal College of Pathologists1993
- Fellow of the Hong Kong Academy of Medicine (Pathology)Fellow of the Hong Kong Academy of Medicine (Pathology)1995
Hong Kong Academy of Medicine fellowships
- FHKCPathFellow, The Hong Kong College of Pathologists1995
Source: Hong Kong Academy of Medicine Fellows Register, checked 12 Sep 2026
Locations
Department of Pathology Queen Mary Hospital Pokfulam Hong Kong
Fax: +852 2872 5197
Insurance
Insurance plans being compiled
We're collecting insurance plan data per clinic. For confirmation, contact the clinic directly.
Are you Dr. Khoo Ui Soon? Claim page and update insurance →
FAQ
Is Dr. Khoo Ui Soon any good?
Dr. Khoo Ui Soon is a registered Pathology specialist in Hong Kong. Qualifications and registration come from the Hong Kong Medical Council. ok.med does not rate or rank doctors.
What does Dr. Khoo Ui Soon do?
Dr. Khoo Ui Soon practises in Pathology.
Are you Dr. Khoo Ui Soon? Claim this page to update and manage.
ClaimResearch and publications
30 papers · 12 most recent shown
Filter by paper topic
Topics come from medical classifications on these PubMed papers, not from the doctor's listed services.
- Multidimensional Artificial Intelligence-Based Cancer Progression Prediction in Oral Leukoplakia.Journal of dental research · 2026
- The Splice Variant of the NCOR2 Gene BQ323636.1 Modulates ACSL4 Expression to Enhance Fatty Acid Metabolism and Support of Tumor Growth in Breast Cancer.International journal of molecular sciences · 2025
- Ivabradine induces RAD51 degradation, potentiating PARP inhibitor efficacy in non-germline BRCA pathogenic variant triple-negative breast cancer.Journal of translational medicine · 2025
- BQ323636.1 Employs the AR-CCRK Axis to Modulate the Expression of KU70 to Interfere with Non-Homologous End Joining Mediated DNA Repair Mechanism.Cells · 2025
- Students' motivation and engagement in interprofessional education: the mediating role of peer relatedness.Medical education online · 2024
- Correction: Tsoi et al. Overexpression of BQ323636.1 Modulated AR/IL-8/CXCR1 Axis to Confer Tamoxifen Resistance in ER-Positive Breast Cancer. <i>Life</i> 2022, <i>12</i>, 93.Life (Basel, Switzerland) · 2024
- Overexpression of BQ323636.1 contributes to anastrozole resistance in AR+ve/ER+ve breast cancer.The Journal of pathology · 2023
- SRSF5 Regulates the Expression of BQ323636.1 to Modulate Tamoxifen Resistance in ER-Positive Breast Cancer.Cancers · 2023
- Androgen Receptor as an Emerging Feasible Biomarker for Breast Cancer.Biomolecules · 2022
- Modulating the Activity of Androgen Receptor for Treating Breast Cancer.International journal of molecular sciences · 2022
- Targeting Ribosome Biogenesis to Combat Tamoxifen Resistance in ER+ve Breast Cancer.Cancers · 2022
- Overexpression of BQ323636.1 Modulated AR/IL-8/CXCR1 Axis to Confer Tamoxifen Resistance in ER-Positive Breast Cancer.Life (Basel, Switzerland) · 2022
Publication data comes from PubMed / Europe PMC and is matched automatically by name and affiliation. Every entry links to the source.
For reference only. Not medical advice. Read full disclaimer